U.S. Stem Cell, Inc.

OTCPK:USRM Stock Report

Market Cap: US$66.2k

U.S. Stem Cell Management

Management criteria checks 2/4

U.S. Stem Cell's CEO is Mike Tomas, appointed in Jun 2010, has a tenure of 14.58 years. directly owns 1.51% of the company’s shares, worth $1.00K. The average tenure of the management team and the board of directors is 11.7 years and 18 years respectively.

Key information

Mike Tomas

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure14.6yrs
CEO ownership1.5%
Management average tenure11.7yrs
Board average tenure18yrs

Recent management updates

No updates

Recent updates

CEO Compensation Analysis

How has Mike Tomas's remuneration changed compared to U.S. Stem Cell's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2022n/an/a

-US$3m

Sep 30 2022n/an/a

-US$3m

Jun 30 2022n/an/a

-US$3m

Mar 31 2022n/an/a

-US$3m

Dec 31 2021US$327kUS$327k

-US$3m

Sep 30 2021n/an/a

-US$3m

Jun 30 2021n/an/a

-US$4m

Mar 31 2021n/an/a

-US$3m

Dec 31 2020US$630kUS$130k

-US$3m

Sep 30 2020n/an/a

-US$3m

Jun 30 2020n/an/a

-US$3m

Mar 31 2020n/an/a

-US$4m

Dec 31 2019US$2mUS$881k

-US$4m

Sep 30 2019n/an/a

-US$4m

Jun 30 2019n/an/a

-US$2m

Mar 31 2019n/an/a

-US$3m

Dec 31 2018US$3mUS$1m

-US$2m

Compensation vs Market: Insufficient data to establish whether Mike's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Insufficient data to compare Mike's compensation with company performance.

CEO

Mike Tomas (58 yo)

14.6yrs

Tenure

Mr. Michael Tomas, also known as Mike, has been the Chief Executive Officer and President of U.S. Stem Cell, Inc. since June 18, 2010. Mr. Tomas serves as the Vice President of Corporate Affairs of Pharmed...

Leadership Team

NamePositionTenureCompensationOwnership
Michael Tomas
CEO, President14.6yrsno data1.51%
$ 1.0k
Colleen Robb
Senior Compliance Officer11.3yrsno datano data
Phil Posa
Senior Vice President of U.S. & International Sales6.3yrsno datano data
Evelyn Flores
Corporate Controller11.7yrsno datano data
Sergio Pinski
Medical Director & Member of Scientific Advisory Board20.1yrsno datano data

11.7yrs

Average Tenure

Experienced Management: USRM's management team is seasoned and experienced (11.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Michael Tomas
CEO, President14.6yrsno data1.51%
$ 1.0k
Sergio Pinski
Medical Director & Member of Scientific Advisory Boardno datano datano data
Robert A. Tassel
Member of Scientific Advisory Boardno datano datano data
William Murphy
Chairman Emeritus21.6yrsno data0.0096%
$ 6.4
George Magovern
Member of Scientific Advisory Boardno datano datano data
Syde Taheri
Member of Scientific Advisory Boardno datano datano data
Marc Penn
Member of Scientific Advisory Boardno datano datano data
Keith March
Member of Scientific Advisory Boardno datano datano data
Miranda Grounds
Member of Scientific Advisory Boardno datano datano data
Christopher O'Connor
Member of Scientific Advisory Boardno datano datano data
Jorge Genovese
Member of Scientific Advisory Board18yrsno datano data
Doris Taylor
Member of Scientific Advisory Boardno datano datano data

18.0yrs

Average Tenure

83yo

Average Age

Experienced Board: USRM's board of directors are seasoned and experienced ( 18 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 16:58
End of Day Share Price 2024/12/31 00:00
Earnings2022/12/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

U.S. Stem Cell, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution